Search research articles
Contact Us
Filters
Showing results (31-40 of 73) with videos related to
Page
of 8
Sort By:
JCO Clinical Cancer Informatics
|
December 15, 2021
Applications of Artificial Intelligence in Pediatric Oncology: A Systematic Review
Siddhi Ramesh, Sukarn Chokkara, Timothy Shen, et al.
Journal of Clinical Apheresis
|
October 21, 2021
Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE)
Ajay Major, Timothy Carll, Clarence W Chan, et al.
Leukemia & Lymphoma
|
March 10, 2025
Patient and care partner perspectives on treatment decision-making in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): a Global nLPHL One Working Group (GLOW) study
Ajay Major, Monica Palese, Anna Jones, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 19, 2024
DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas
Jessica Allen, Diana Abbott, Joy Eskandar, et al.
Blood Cancer Journal
|
October 7, 2024
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
Benjamin A Derman, Ajay Major, Jennifer Cooperrider, et al.
Leukemia & Lymphoma
|
February 9, 2021
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature
Ajay Major, Jennifer Collins, Caroline Craney, et al.
European Journal of Haematology
|
February 2, 2023
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
Benjamin A Derman, Ajai Chari, Jeffrey Zonder, et al.
Blood Advances
|
December 27, 2023
Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial
Bradley Haverkos, Jasmine Zain, Manali Kamdar, et al.
Blood Advances
|
February 10, 2023
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
Benjamin A Derman, Jeffrey Zonder, Donna Reece, et al.
Blood Cancer Journal
|
May 29, 2024
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Benjamin A Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 73) with videos related to
Sort By:
Page
of 8
JCO Clinical Cancer Informatics
|
December 15, 2021
Applications of Artificial Intelligence in Pediatric Oncology: A Systematic Review
Siddhi Ramesh, Sukarn Chokkara, Timothy Shen, et al.
Journal of Clinical Apheresis
|
October 21, 2021
Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE)
Ajay Major, Timothy Carll, Clarence W Chan, et al.
Leukemia & Lymphoma
|
March 10, 2025
Patient and care partner perspectives on treatment decision-making in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): a Global nLPHL One Working Group (GLOW) study
Ajay Major, Monica Palese, Anna Jones, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 19, 2024
DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas
Jessica Allen, Diana Abbott, Joy Eskandar, et al.
Blood Cancer Journal
|
October 7, 2024
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
Benjamin A Derman, Ajay Major, Jennifer Cooperrider, et al.
Leukemia & Lymphoma
|
February 9, 2021
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature
Ajay Major, Jennifer Collins, Caroline Craney, et al.
European Journal of Haematology
|
February 2, 2023
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
Benjamin A Derman, Ajai Chari, Jeffrey Zonder, et al.
Blood Advances
|
December 27, 2023
Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial
Bradley Haverkos, Jasmine Zain, Manali Kamdar, et al.
Blood Advances
|
February 10, 2023
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
Benjamin A Derman, Jeffrey Zonder, Donna Reece, et al.
Blood Cancer Journal
|
May 29, 2024
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Benjamin A Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, et al.
Page
of 8